iFLYTEK donates AI technology, other supplies to battle coronavirus

Another AI provider has donated key resources to help healthcare workers currently combating the deadly coronavirus outbreak. iFLYTEK, an AI and speech technology company based out of China, has contributed $1.44 million in medical equipment and supplies to the cause.

“iFLYTEK's intelligent medical and educational technologies provide unique help and assistance to the government and the public in this extremely complex and difficult period,” Dawei Duan,  iFLYTEK chief financial officer, said in a prepared statement. “We are also employing our smart online classroom technology to provide a way for students to keep learning when schools are temporarily suspended. iFLYTEK will continue to provide our world-leading AI expertise and tools to help those working to contain and defeat this virus as long as needed.”

The company has also donated 3,000 protective suits, more than 12,000 protective masks and more than 13,000 goggles to workers from area hospitals. Healthcare providers in Wuhan—including Zhongnan Hospital of Wuhan University and Third People’s Hospital of Wuhan City—are among those who have received the donations.

On Jan. 29, Abu Dhabi-based Group 42 announced a donation of its own to healthcare workers battling the disease.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.